Novavax (NVAX) Files for Sale of $150M Shares

Novavax (NASDAQ: NVAX) disclosed:

On March 2, 2020, Novavax, Inc. (the “Company”), filed a prospectus supplement with the Securities and Exchange Commission which contemplates the sale of up to $150,000,000 of shares of the Company’s common stock (the “Shares”) from time to time in at-the-market offerings pursuant to an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (the “Sales Agent”), dated as of March 2, 2020 (the “March 2020 Sales Agreement”). Sales pursuant to the March 2020 Sales Agreement will be made only upon instructions by the Company to the Sales Agent, and the Company cannot provide any assurances that it will issue any Shares pursuant to the March 2020 Sales Agreement.

You May Also Be Interested In

• Novavax's Nuvaxovid wins approval in U.S., EU, Japan for 2026-2027
• Flowers Foods (FLO) files mixed shelf
• BrenX signs deal to buy land in Hungary for $190,000